SEARCH

SEARCH BY CITATION

References

  • 1
    Begg EJ & Barclay MLAminoglycosides—50 years on. Br J Clin Pharmacol1995; 39: 597 603
  • 2
    Benet LZ & Williams RLDesign and optimisation of dosage regimens. InThe Pharmacological Basis of Therapeutics, Eight Edition, eds Gilman AG, Rall TW, Nies AS, Taylor P, New York: Pergamon Press, 1990: 1650 1735
  • 3
    Zaske DE, Cipolle RJ, Solem LD, Strate RGRapid individualization of gentamicin dosage regimens in 66 burn patients. Burns1981; 7: 215 220
  • 4
    Hoey LL, Tschida SJ, Rotschafer JC, Guay DRP, Vance-Bryan KWide variation in single daily dose aminoglycoside pharmacokinetics in patients with burn injuries. J Burn Care Rehabil1997; 18: 116 124
  • 5
    Barclay ML & Begg EJAminoglycoside toxicity and relation to dose regimen. Adverse Drug React Toxicol Rev1994; 13: 207 234
  • 6
    Noone P, Parsons TMC, Pattison JR, Slack RCB, Garfield-Davies D, Hughes KExperience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J1974; 1: 477 481
  • 7
    Moore RD, Smith CR, Lietman PSThe association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis1984; 149: 443 448
  • 8
    Moore RD, Smith CR, Lietman PSAssociation of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med1984; 77: 657 662
  • 9
    Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman POnce versus thrice daily gentamicin in patients with serious infections. Lancet1993; 341: 335 339
  • 10
    Konrad F, Wagner R, Neumeister B, Rommel H, Georgieff MStudies on drug monitoring in thrice and once daily treatment with aminoglycosides. Intensive Care Med1993; 19: 215 220
  • 11
    Ter Braak EW, De Vries PJ, Bouter KP,et al. Once-daily dosing regimen for aminoglycoside plus B-lactam combination therapy of serious bacterial infections: Comparative trial with netilmicin plus ceftriaxone. Am J Med1990; 89: 58 66
  • 12
    Begg EJ, Barclay ML, Duffull SBA suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol1995; 39: 605 609
  • 13
    Morike K, Schwab M, Klotz UUse of aminoglycosides in elderly patients—pharmacokinetic and clinical considerations. Drugs & Aging1997; 10: 259 277
  • 14
    Sawchuk RJ, Zaske DE, Cipolle RJ, Wargin WA, Strate RGKinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther1977; 21: 362 369
  • 15
    Begg EJ, Atkinson HC, Jeffery GM, Taylor NWIndividualised aminoglycoside dosage based on pharmacokinetic analysis is superior to dosage based on physician intuition at achieving target plasma drug concentrations. Br J Clin Pharmacol1989; 28: 137 141
  • 16
    Hickling K, Begg E, Moore MLA prospective randomised trial comparing individualised pharmacokinetic dosage prediction for aminoglycosides with prediction based on estimated creatinine clearance in critically ill patients. Intensive Care Med1989; 15: 233 237
  • 17
    Burton ME, Brater DC, Chen PS, Day RB, Huber PJ, Vasko MRlA Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther1985; 37: 349 355
  • 18
    MacGowan A & Reeves DSerum aminoglycoside concentrations: the case for routine monitoring. J Antimicrob Agents1994; 34: 829 837
  • 19
    Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Qintiliani RExperience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother1995; 39: 650 655
  • 20
    El Bakri F, Pallett A, Smith AG, Duncombe ASOtotoxicity induced by once-daily gentamicin. Lancet1998, 351: 1407 1408
  • 21
    Duffull SB, Kirkpatrick CMJ, Begg EJComparison of two Bayesian approaches to dose-individualisation for once daily dosing regimens. Br J Clin Pharmacol1997; 43: 125 135
  • 22
    Hickling KG, Begg EJ, Perry RE, Atkinson HC, Sharman JRSerum aminoglycoside clearance is predicted as poorly by renal aminoglycoside clearance as by creatinine clearance in critically ill patients. Crit Care Med1991; 19: 1041 1047
  • 23
    Trissel LA (ed)Handbook on Injectable Drugs. Sixth Edition, Bethesda, USA: Am Soc Hospital Pharmacists, 1990: 358 361
  • 24
    Destache CJ, Meyer SK, Rowley KMDoes accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis. Ther Drug Monitor1990; 12: 427 433
  • 25
    Crist KD, Nahata MC, Ety JPostive impact of a therapeutic drug-monitoring program on total aminoglycoside dose and cost of hospitalization. Ther Drug Monitor1987; 9: 306 310
  • 26
    Nicolau DP, Wu AHB, Finocchiaro S,et al. Once-daily aminoglycoside dosing: Impact on requests and costs of therapeutic drug monitoring. Ther Drug Monitor1996; 18: 263 266
  • 27
    Edwards DJ & Pancorbo SRoutine monitoring of serum vancomycin concentrations: waiting for proof of its value. Clin Pharm1987; 6: 652 654
  • 28
    Freeman CD, Quintiliani R, Nightingale CHVancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother1993; 27: 594 598
  • 29
    Saunders NJWhy monitor peak vancomycin concentrations? Lancet1994; 344: 1748 1750
  • 30
    Duffull SB & Begg EJVancomycin toxicity. What is the evidence for dose dependency? Adverse Drug React Toxicol Rev1994; 13: 103 114
  • 31
    Duffull SB, Chambers ST, Begg EJHow vancomycin is used in clinical practice—a survey. Aust NZ J Med1993; 23: 662 666
  • 32
    Geraci JE, Heilman FR, Nichols DR, Wellman WEAntibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis. Staff Meetings of the Mayo Clinic1958; 33: 172 181
  • 33
    Rybak MJ, Albrecht LM, Boike SC, Chandresekar PHNephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother1990; 25: 679 687
  • 34
    Cimino MA, Rotstein C, Slaughter RL, Emrich LJRelationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med1987; 83: 1091 1096
  • 35
    Garrelts JC, Godley PJ, Horton MW, Karboski JAAccuracy of Bayesian, Sawchuk-Zaske, and nomogram dosing methods for vancomycin. Clin Pharm1987; 6: 795 799
  • 36
    Healy DP, Sahai JV, Fuller SH, Polk REVancomycin-induced histamine release and ‘red man syndrome’: Comparison of 1 and 2 hour infusions. Antimicrob Agents Chemother1990; 34: 550 555
  • 37
    Lake KD & Peterson CDA simplified dosing method for initiating vancomycin therapy. Pharmacotherapy1985; 5: 340 344
  • 38
    Matzke GR, McGory RW, Halstenson CE, Keane WFPharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother1984; 25: 433 437
  • 39
    Moellering RC JrPharmacokinetics of vancomycin. J Antimicrob Chemother1984; 14: 43 52
  • 40
    Ackerman BH, Olsen KM, Padilla CBErrors in assuming a one-compartment model for vancomycin. Ther Drug Monit1990; 12: 304 305
  • 41
    Burton ME, Gentle DL, Vasko MREvaluation of a Bayesian method for predicting vancomycin dosing. DICP1989; 23: 294 299
  • 42
    Hurst AK, Yoshinaga MA, Mitani GH, Foo KA, Jelliffe RW, Harrison ECApplication of a Bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrob Agents Chemother1990; 34: 1165 1171
  • 43
    Pryka RD, Rodvold KA, Garrison M, Rotschafer JCIndividualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models. Ther Drug Monit1989; 11: 450 454
  • 44
    Hu MW, Anne L, Forni T, Gottwald KMeasurement of vancomycin in renally impaired. Analytical Abstracts1991; 53: 1321 1322
  • 45
    White LO, Edwards R, Holt HA, Lovering AM, Finch RG, Reeves DSThe in-vitro degradation at 37° C of vancomycin in serum, CAPD fluid and phosphate-buffered saline. J Antimicrob Chemother1988; 22: 739 745
  • 46
    Morse GD, Nairn KD, Bertino SJ, Walshe JJOverestimation of vancomycin concentrations utilising fluoescence polarising immunoassay in patients on peritoneal dialysis. Ther Drug Monitor1987; 9: 212 215
  • 47
    Welty TE & Copa AKImpact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother1994; 28: 1335 1399
  • 48
    Lake KD & Peterson CDEvaluation of a method for individualising vancomycin therapy: experience in 205 patients. Pharmacotherapy1988; 8: 284 286
  • 49
    Brogden RN & Peters DHTeicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs1994; 47: 823 854
  • 50
    Wood MJThe comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother1996; 37: 209 222
  • 51
    Bourget P, Lesne-Hulin A, Sertin A, Maillot A, Alaya M, Martin CFluorescence polarization immunoassay: Does it always represent a reliable method to monitor treatment with teicoplanin? Comparison with data obtained by high-performance liquid chromatography. Int J Pharmaceut1997; 146: 167 174
  • 52
    Reeves DS, MacGowan AP, Holt HA, Lovering AM, Warnock DW, White LOTherapeutic monitoring of antimicrobials. J Antimicrob Chemother1995; 35: 213 226
  • 53
    Steer JA, Papini RP, Wilson AP,et al. Pharmacokinetics of a single dose of teicoplanin in burn patients. J Antimicrob Chemother1996; 37: 545 553
  • 54
    Sahai JV, Healy DP, Shelton MJ, Miller JS, Ruberg SJ, Polk RComparison of a vancomycin and teicoplanin-induced histamine release and ‘red man syndrome’. Antimicrob Agents Chemother1990; 34: 765 769
  • 55
    Summers KK, Hardin TC, Gore SJ, Graybill JRTherapeutic drug monitoring of systemic antifungal therapy. J Antimicrob Chemother1997; 40: 753 764
  • 56
    Lyman CA & Walsh TJSystemically administered antifungal agents. A review of their clinical pharmacology and therapeutical applications. Drugs1992; 44 (1): 9 35
  • 57
    Kauffman CA & Frame PTBone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother1977; 11: 244 247
  • 58
    Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles CAToxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med1987; 83: 236 242
  • 59
    Viviani MAFlucytosine—what is its future? J Antimicrob Chemother1995; 35: 241 244
  • 60
    Tucker RM, Denning DW, Hanson LH,et al. Interaction of azoles with rifampin, phenytoin and carbamazepine: in vitro and clinical observations. Clin Infect Dis1992; 14: 165 174
  • 61
    Kintzel PE, Rollins CJ, Yee WJ, List AFLow itraconazole serum concentrations following administration of itraconazole suspension to critically ill allogenic bone marrow transplant recipients. Ann Pharmacother1995; 29: 140 143
  • 62
    Tricot G, Joosten G, Boogaetrs MA, Van de Pitte J, Cauwenbergh GKetoconazole vs itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two randomised studies. Reviews of Infectious Diseases1987; 9 (Suppl.1): 94 99
  • 63
    Van Custen JThe in vitro antifungal spectrum of itraconazole. Mycoses1989; 32: 7 13
  • 64
    Poirier JM, Lebot M, Descamps P, Levy M, Cheymol GDetermination of itraconazole and its active metabolite in plasma by column liquid chromatography. Ther Drug Monit1994; 16: 596 601